|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
|
US5436150A
(en)
|
1992-04-03 |
1995-07-25 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
|
|
US5487994A
(en)
|
1992-04-03 |
1996-01-30 |
The Johns Hopkins University |
Insertion and deletion mutants of FokI restriction endonuclease
|
|
US5356802A
(en)
|
1992-04-03 |
1994-10-18 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
|
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
|
WO1998014179A1
(en)
|
1996-10-01 |
1998-04-09 |
Cima Labs Inc. |
Taste-masked microcapsule compositions and methods of manufacture
|
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
PT904392E
(pt)
|
1996-10-17 |
2001-06-29 |
Oxford Biomedica Ltd |
Vectores retrovirais
|
|
GB9622500D0
(en)
|
1996-10-29 |
1997-01-08 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
|
US8206965B2
(en)
|
2002-03-15 |
2012-06-26 |
Cellectis S.A. |
Hybrid and single chain meganucleases and use thereof
|
|
EP1504092B2
(en)
|
2002-03-21 |
2014-06-25 |
Sangamo BioSciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US9447434B2
(en)
|
2002-09-05 |
2016-09-20 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
|
AU2003290518A1
(en)
|
2002-09-06 |
2004-04-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions concerning designed highly-specific nucleic acid binding proteins
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
EP1591521A1
(en)
|
2004-04-30 |
2005-11-02 |
Cellectis |
I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
|
|
US20090226474A1
(en)
|
2004-05-27 |
2009-09-10 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
KR20070060115A
(ko)
|
2004-09-16 |
2007-06-12 |
상가모 바이오사이언스 인코포레이티드 |
단백질 생산을 위한 조성물 및 방법
|
|
ATE466933T1
(de)
|
2005-03-15 |
2010-05-15 |
Cellectis |
I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
|
|
WO2006097784A1
(en)
|
2005-03-15 |
2006-09-21 |
Cellectis |
I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
US9316646B2
(en)
|
2009-04-23 |
2016-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ROR1 antibodies
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
EP2646469B1
(en)
|
2010-12-01 |
2017-11-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Chimeric rabbit/human ror1 antibodies
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2013039857A1
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
EP4397759A3
(en)
|
2012-10-23 |
2024-10-09 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
WO2014131833A1
(en)
|
2013-02-27 |
2014-09-04 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Gene editing in the oocyte by cas9 nucleases
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
|
WO2015191693A2
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
AU2015362618B2
(en)
|
2014-12-16 |
2022-01-27 |
C3J Therapeutics, Inc. |
Compositions of and methods for in vitro viral genome engineering
|
|
GB201515351D0
(en)
|
2015-08-28 |
2015-10-14 |
Cancer Res Technology |
Antibody
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
AU2017295704B2
(en)
|
2016-07-13 |
2023-07-13 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
GB201621889D0
(en)
|
2016-12-21 |
2017-02-01 |
Autolus Ltd |
Cell
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018200582A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
|
US20210069241A1
(en)
*
|
2017-10-20 |
2021-03-11 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
|
EP3723774A4
(en)
|
2017-12-15 |
2021-09-08 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
|
|
WO2019165067A1
(en)
|
2018-02-21 |
2019-08-29 |
Bristol-Myers Squibb Company |
Camk2d antisense oligonucleotides and uses thereof
|
|
CA3093919A1
(en)
*
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
EP3765094A4
(en)
*
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
|
|
EP3830114A4
(en)
|
2018-07-31 |
2022-08-03 |
Washington University |
USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT
|
|
WO2020131862A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
|
WO2020237040A1
(en)
|
2019-05-22 |
2020-11-26 |
KSQ Therapeutics, Inc. |
Nr4a super-repressors and methods of use thereof
|
|
KR20240028362A
(ko)
|
2021-05-28 |
2024-03-05 |
라이엘 이뮤노파마, 인크. |
Nr4a3-결핍 면역 세포 및 이의 용도
|
|
KR20240027676A
(ko)
|
2021-06-02 |
2024-03-04 |
라이엘 이뮤노파마, 인크. |
Nr4a3-결핍 면역 세포 및 이의 용도
|